We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Median Technologies | EU:ALMDT | Euronext | Ordinary Share |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.18 | 5.29% | 3.58 | 3.665 | 3.60 | 3.635 | 3.235 | 3.44 | 65,855 | 16:30:05 |
Regulatory News:
The shareholders of Median Technologies (ALMDT:PA) (Paris:ALMDT) are invited to participate at the Shareholders’ Ordinary General Meeting which will be held on Tuesday October 10, 2023, at 11:00 AM CEST at PDGB, 174 avenue Victor Hugo – 75116 Paris.
All useful information relating to this Shareholders’ General Meeting is regularly updated on Median Technologies’ website.
Shareholders may exercise their voting rights before the holding of the Shareholders’ General Meeting, either by returning their postal voting form, or by giving proxy. The detailed procedures relating to the exercise of the right to vote are specified in the notice of the Shareholders’ General Meeting, available here on Median’s website
The preliminary notice of the Shareholders’ General Meeting has been published in the BALO (Bulletin des annonces légales obligatoires) on September 4, 2023.
The documents referred to in Article R.225-83 of the French Commercial Code are made available to Shareholders as from the date of the convening notice for the Meeting in accordance with applicable regulations:
The documents to be communicated within the context of the Shareholders’ General Meeting may be consulted and downloaded on Median Technologies’ website under the “Shareholder Meetings” section here.
About Median Technologies: Median Technologies provides innovative imaging solutions and services to advance healthcare for everyone. We harness the power of medical images by using the most advanced Artificial Intelligence technologies, to increase the accuracy of diagnosis and treatment of many cancers and other metabolic diseases at their earliest stages and provide insights into novel therapies for patients. Our iCRO solutions for medical image analysis and management in oncology trials and iBiopsy®, our AI-powered imaging platform for the development of software as medical devices (SaMD) help biopharmaceutical companies and clinicians to bring new treatments and diagnose patients earlier and more accurately. This is how we are helping to create a healthier world.
Founded in 2002, based in Sophia-Antipolis, France, with a subsidiary in the US and another one in Shanghai, Median has received the label “Innovative company” by the BPI and is listed on Euronext Growth market (Paris). FR0011049824– ticker: ALMDT. Median is eligible for the French SME equity savings plan scheme (PEA-PME). For more information: www.mediantechnologies.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20230921382559/en/
Median Technologies Emmanuelle Leygues Head of Corporate Marketing & Financial Communications +33 6 10 93 58 88 emmanuelle.leygues@mediantechnologies.com
Press - ALIZE RP Caroline Carmagnol +33 6 64 18 99 59 median@alizerp.com
Investors - ACTIFIN Ghislaine Gasparetto +33 6 21 10 49 24 ggasparetto@actifin.fr
1 Year Median Technologies Chart |
1 Month Median Technologies Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions